Work

Plain language summary: treatment of Sjögren’s disease with dazodalibep

Year: 2025

Type: article

Abstract: Plain Language SummaryWhat is this summary about?Dazodalibep is an experimental medicine being tested to treat the symptoms of patients with Sjögren’s disease (abbreviated as SjD). SjD is a long-lasting, autoimmune illness that affects the entire body and can result in pain, fatigue, and dry eyes and mouth. Here we summarize results from a phase 2 clinical trial, originally published in Nature Medicine, which examined how well dazodalibep worked in two groups of participants with SjD: (1) participants with high disease activity and (2) participants with intense symptoms but low disease activity. To date, clinical trials for SjD have focused largely on patients with high disease activity but excluded patients with intense symptoms (dry eyes and mouth, fatigue, and muscle and joint pain that spreads across the body) but low disease activity. While medicines are available to manage SjD symptoms, no medications are currently approved to treat the underlying cause of SjD.What were the results?In this trial, dazodalibep significantly reduced disease activity and substantially improved symptoms of SjD in group 1 and significantly improved symptoms of SjD in group 2. Specifically, participants who received dazodalibep were not as tired, had less pain, and experienced less intense symptoms of dry eyes and mouth.What do the results mean?Results from this trial showed that dazodalibep may be a new potential medication for two types of patients with SjD with unmet treatment needs.

Source: Immunotherapy

DOI: 10.1080/1750743x.2025.2572284